+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuropathic Pain Drug"

From
Neuropathic Pain Market Report 2025 - Product Thumbnail Image

Neuropathic Pain Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Neuropathic Pain - Pipeline Insight, 2024 - Product Thumbnail Image

Neuropathic Pain - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Diabetic Neuropathic Pain - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Neuropathic Pain - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
From
From
Peripheral Neuropathic Pain - Pipeline Insight, 2024 - Product Thumbnail Image

Peripheral Neuropathic Pain - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • March 2025
  • 898 Pages
  • Global
From
From
Diabetic Neuropathic Pain Market - Product Thumbnail Image

Diabetic Neuropathic Pain Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Peripheral Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Peripheral Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Chronic Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Chronic Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Loading Indicator

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more